• 1
    Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 191520.
  • 2
    Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104: 97984.
  • 3
    Bäckhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 1571823.
  • 4
    Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 102731.
  • 5
    Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51: 110112.
  • 6
    Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 110705.
  • 7
    Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology:human gut microbes associated with obesity. Nature 2006; 444: 10223.
  • 8
    Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 4804.
  • 9
    Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15: 154658.
  • 10
    Cani PD, Delzenne NM. Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. Curr Opin Pharmacol 2009; 9: 73743.
  • 11
    Musso G, Gambino R, Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 2010; 21: 7683.
  • 12
    Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009; 587: 41538.
  • 13
    Vrieze A, Holleman F, Zoetendal EG, De Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 2010; 53: 60613.
  • 14
    Bäckhed F, Crawford PA. Coordinated regulation of the metabolome and lipidome at the host-microbial interface. Biochim Biophys Acta 2010; 1801: 2405.
  • 15
    Reinhardt C, Reigstad CS, Bäckhed F. Intestinal microbiota during infancy and its implications for obesity. J Pediatr Gastroenterol Nutr 2009; 48: 24956.
  • 16
    Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783801.
  • 17
    Beutler B. Inferences, questions and possibilities in toll-like receptor signalling. Nature 2004; 430: 25763.
  • 18
    Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 82335.
  • 19
    Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol 2008; 8: 92334.
  • 20
    Johnson GB, Riggs BL, Platt JL. A genetic basis for the “Adonis” phenotype of low adiposity and strong bones. FASEB J 2004; 18: 12824.
  • 21
    Tsukumo DML, Carvalho-Filho MA, Carvalheira JBC et al. Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 198698.
  • 22
    Saberi M, Woods NB, De Luca C et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009; 10: 41929.
  • 23
    Vijay-Kumar M, Aitken JD, Carvalho FA et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 2010; 328: 22831.
  • 24
    Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 11119.
  • 25
    Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 4305.
  • 26
    Goto T, Eden S, Nordenstam G, Sundh V, Svanborg-Eden C, Mattsby-Baltzer I. Endotoxin levels in sera of elderly individuals. Clin Diagn Lab Immunol 1994; 1: 6848.
  • 27
    Wiedermann CJ, Kiechl S, Dunzendorfer S et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the bruneck study. J Am Coll Cardiol 1999; 34: 197581.
  • 28
    Bölke E, Jehle PM, Storck M, Nothnagel B, Stanescu A, Orth K. Endotoxin release and endotoxin neutralizing capacity during colonoscopy. Clin Chim Acta 2001; 303: 4953.
  • 29
    Niebauer J, Volk H-D, Kemp M et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 183842.
  • 30
    Nadhazi Z, Takats A, Offenmuller K, Bertok L. Plasma endotoxin level of healthy donors. Acta Microbiol Immunol Hung 2002; 49: 1517.
  • 31
    Creely SJ, McTernan PG, Kusminski CM et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292: E7407.
  • 32
    Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 176172.
  • 33
    Reigstad CS, Lunden GO, Felin J, Backhed F. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS ONE 2009; 4: e5842.
  • 34
    Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002; 195: 55970.
  • 35
    Sabesin SM, Frase S. Electron microscopic studies of the assembly, intracellular transport, and secretion of chylomicrons by rat intestine. J Lipid Res 1977; 18: 496511.
  • 36
    Ghoshal S, Witta J, Zhong J, De Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 907.
  • 37
    Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 128692.
  • 38
    Amar J, Burcelin R, Ruidavets JB et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008; 87: 121923.
  • 39
    Brun P, Castagliuolo I, Leo VD et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G51825.
  • 40
    Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet–induced obesity and diabetes in mice. Diabetes 2008; 57: 147081.
  • 41
    Cani PD, Neyrinck AM, Fava F et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 237483.
  • 42
    Cani PD, Possemiers S, Van de Wiele T et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091103.
  • 43
    Cinti S, Mitchell G, Barbatelli G et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46: 234755.
  • 44
    Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 17584.
  • 45
    Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796808.
  • 46
    Xu H, Barnes GT, Yang Q et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 182130.
  • 47
    Wostmann BS, Larkin C, Moriarty A, Bruckner-Kardoss E. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci 1983; 33: 4650.
  • 48
    Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 301525.
  • 49
    Nguyen MT, Favelyukis S, Nguyen AK et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 3527992.
  • 50
    Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007; 27: 8491.
  • 51
    Gao Z, Hwang D, Bataille F et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J Biol Chem 2002; 277: 4811521.
  • 52
    Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 2000; 275: 904754.
  • 53
    Arkan MC, Hevener AL, Greten FR et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005; 11: 1918.
  • 54
    Solinas G, Vilcu C, Neels JG et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007; 6: 38697.
  • 55
    Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16: 22831.
  • 56
    Monaco C, Gregan S, Navin T, Foxwell B, Davies A, Feldmann M. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 2009; 120: 24629.
  • 57
    Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 18592.
  • 58
    Michelsen K, Wong M, Shah P et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004; 101: 1067984.
  • 59
    Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by toll-like receptor 2. J Clin Invest 2005; 115: 314956.
  • 60
    Björkbacka H, Kunjathoor V, Moore K et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10: 41621.
  • 61
    Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 2008; 7: 36575.
  • 62
    Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 2002; 8: 12438.
  • 63
    Castrillo A, Joseph SB, Vaidya SA et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 2003; 12: 80516.
  • 64
    Smoak KA, Aloor JJ, Madenspacher J et al. Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Cell Metab 2010; 11: 493502.
  • 65
    Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000; 20: 141720.
  • 66
    Desvarieux M, Demmer R, Rundek T et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005; 111: 57682.
  • 67
    Mei C, He P, Cheng B, Liu W, Wang Y, Wan J. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR a and PPAR g-dependent pathways. Cell Biol Int 2009; 33: 3018.
  • 68
    Ott SJ, El Mokhtari NE, Musfeldt M et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006; 113: 92937.
  • 69
    Chen S, Sorrentino R, Shimada K et al. Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol 2008; 181: 718693.
  • 70
    Jaff M, Dale R, Creager M et al. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1). Circulation 2009; 119: 4528.
  • 71
    Andraws R, Berger J, Brown D. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 26417.
  • 72
    Muhlestein J. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 2003; 14: 60514.
  • 73
    Mattila KJ, Nieminen MS, Valtonen VV et al. Association between dental health and acute myocardial infarction. BMJ 1989; 298: 77981.
  • 74
    Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000; 71: 155460.
  • 75
    Kozarov EV, Dorn BR, Shelburne CE, Dunn WA Jr, Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005; 25: e178.
  • 76
    Stelzel M, Conrads G, Pankuweit S et al. Detection of Porphyromonas gingivalis DNA in aortic tissue by PCR. J Periodontol 2002; 73: 86870.
  • 77
    Gaetti-Jardim E Jr, Marcelino SL, Feitosa AC, Romito GA, Avila-Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. J Med Microbiol 2009; 58: 156875.
  • 78
    Gibson FC III, Hong C, Chou HH et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 28016.
  • 79
    De Oliveira C, Watt R, Hamer M. Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. BMJ 2010; 340: c2451.
  • 80
    Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 208.
  • 81
    Stepankova R, Tonar Z, Bartova J et al. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J Atheroscler Thromb 2010; Apr 2 (Epub ahead of print).
  • 82
    Wright S, Burton C, Hernandez M et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191: 143742.
  • 83
    Taranto M, Medici M, Perdigon G, Ruiz Holgado A, Valdez G. Effect of Lactobacillus reuteri on the prevention of hypercholesterolemia in mice. J Dairy Sci 2000; 83: 4013.
  • 84
    Andrade S, Borges N. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J Dairy Sci 2009; 76: 46974.
  • 85
    Luoto R, Kalliomäki M, Laitinen K, Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int J Obes (Lond) 2010; Mar 16 (Epub ahead of print).
  • 86
    Kadooka Y, Sato M, Imaizumi K et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr 2010; 64: 63643.
  • 87
    Portugal L, Gonçalves J, Fernandes L et al. Effect of Lactobacillus delbrueckii on cholesterol metabolism in germ-free mice and on atherogenesis in apolipoprotein E knock-out mice. Braz J Med Biol Res 2006; 39: 62935.
  • 88
    Rault-Nania M, Gueux E, Demougeot C, Demigné C, Rock E, Mazur A. Inulin attenuates atherosclerosis in apolipoprotein E-deficient mice. Br J Nutr 2006; 96: 8404.
  • 89
    Cavallini D, Bedani R, Bomdespacho L, Vendramini R, Rossi E. Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study. Lipids Health Dis 2009; 8: doi:10.1186/476-511X-8-1.
  • 90
    Naruszewicz M, Johansson M, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002; 76: 124955.
  • 91
    Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol 2010; 26: 511.